000112446 001__ 112446
000112446 005__ 20240319080947.0
000112446 0247_ $$2doi$$a10.1177/1078155220984229
000112446 0248_ $$2sideral$$a122392
000112446 037__ $$aART-2022-122392
000112446 041__ $$aeng
000112446 100__ $$aMagallón Martínez, Arantxa
000112446 245__ $$aAnalysis of first-line treatment in older patients with metastasic colorectal cancer
000112446 260__ $$c2022
000112446 5060_ $$aAccess copy available to the general public$$fUnrestricted
000112446 5203_ $$aObjective: The purpose of this study was to analyse the effectiveness and safety of first-line treatment of metastatic colorectal cancer (CRCm) in older patients treated in a tertiary hospital.
Material and methods: This was an observational and retrospective study, including patients aged 75 years or older, with CRCm, who received chemotherapy treatment in 2017. The main variables studied were type of treatment, Progression-Free Survival (PFS), Overall Survival (OS), dose reductions, and treatment delays due to adverse events.
Results: A total of 59 patients (71.2% men) with a median age of 76 years were enrolled in this study. About 70% presented colon cancer, with the left colon being the most frequent location. They were treated with 9 different schemes, in most cases using polychemotherapy and biological agents. The median PFS and OS was 12 and 30 months, respectively. A total of 23/59 of patients started treatment at doses lower than recommended in the clinical practice guidelines. In terms of safety, 34/59 of patients had at least one dose reduction, and 30/59 suffered one treatment delay. The most frequent adverse reactions were asthenia, peripheral neuropathy, diarrhoea, and palmoplantar erythrodysesthesia.
Conclusion: Our patients presented baseline clinical characteristics similar to the general adult population, with no tumour characteristics associated with advanced age. The efficacy and toxicity were similar to those in the clinical trials, although our patients had more dose reductions. Considering the heterogeneity of patients and in the absence of clinical trials in the older population, real-life studies can be very useful.
000112446 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000112446 590__ $$a1.3$$b2022
000112446 592__ $$a0.467$$b2022
000112446 591__ $$aPHARMACOLOGY & PHARMACY$$b252 / 278 = 0.906$$c2022$$dQ4$$eT3
000112446 593__ $$aMedicine (miscellaneous)$$c2022$$dQ3
000112446 591__ $$aONCOLOGY$$b226 / 241 = 0.938$$c2022$$dQ4$$eT3
000112446 593__ $$aPharmacology (medical)$$c2022$$dQ3
000112446 593__ $$aOncology$$c2022$$dQ3
000112446 594__ $$a3.0$$b2022
000112446 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000112446 700__ $$aAgustín Ferrández, Maria J.
000112446 700__ $$aPinilla Rello, Andrea
000112446 700__ $$aGimeno-Ballester, Vicente
000112446 700__ $$aEscolano Pueyo, Angel
000112446 700__ $$aPereira Blanco, Olga
000112446 700__ $$0(orcid)0000-0002-7194-8275$$aMalo, Sara$$uUniversidad de Zaragoza
000112446 700__ $$aAbad Sazatornil, Maria R.
000112446 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ.
000112446 773__ $$g28, 1 (2022), 74-81$$pJ. oncol. pharm. pract.$$tJOURNAL OF ONCOLOGY PHARMACY PRACTICE$$x1078-1552
000112446 8564_ $$s1160662$$uhttps://zaguan.unizar.es/record/112446/files/texto_completo.pdf$$yVersión publicada
000112446 8564_ $$s2080378$$uhttps://zaguan.unizar.es/record/112446/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000112446 909CO $$ooai:zaguan.unizar.es:112446$$particulos$$pdriver
000112446 951__ $$a2024-03-18-12:41:58
000112446 980__ $$aARTICLE